Drugging the Undruggable: Targeting Transcription Factors with Small Cyclic Pept
对不可成药的药物进行药物治疗:用小环肽靶向转录因子
基本信息
- 批准号:7981860
- 负责人:
- 金额:$ 230.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-30 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:BindingBiological FactorsCellsCyclic PeptidesCyclosporineCyclosporinsDNA-Protein InteractionDevelopmentDrug Delivery SystemsEngineeringEnsureGenetic TranscriptionHSF1HumanLifeMalignant NeoplasmsMethodsMolecularOrganismPeptide LibraryPharmaceutical PreparationsProcessProteinsReportingRoboticsRouteSTAT3 geneSaccharomyces cerevisiaeScreening procedureSirolimusTechniquesTechnologyTestingYeastscancer therapydrug discoverynovelresearch studytranscription factor
项目摘要
DESCRIPTION (Provided by the applicant)
Abstract: Drugging the Undruggable: Targeting Transcription Factors with Small Cyclic Peptides Transcription factors such as Myc, STAT3 and HSF1 represent key targets for novel cancer therapies. Because they lack the structural features of traditional drug targets, these proteins are often classified as "undruggable." This assumption is perpetuated by the fact that, despite intensive screening efforts using traditional methods, there are few known compounds that target transcription factors. However, potent natural products such as cyclosporine and rapamycin can bind diverse, non-traditional targets that would otherwise be overlooked. Cyclic peptides resemble these natural product macrocycles, and thus have the potential to target promising proteins, including transcription factors, previously dismissed as "undruggable." Novel screening technologies will be required to discover bioactive cyclic peptides (CPs). We recently described a method of genetically encoding CP libraries for phenotypic selections in the yeast Saccharomyces cerevisiae. Since transcription is such a fundamental process, it is critical to perform selections in live organisms to ensure activity and selectivity for the target protein in the context of the full eukaryotic transcriptional machinery. This technique allows tens of millions of CPs to be screened in live cells in a single day without expensive robotics, and provides a rapid route for secondary testing and optimization of hits. This proposal describes application of this method to discover CPs that inhibit diverse human transcription factors implicated in cancer. This will be accomplished by: (1) engineering yeast selection strains that report on protein-protein and protein-DNA interactions of Myc, STAT3 and HSF1, (2) applying CP libraries to the selection strains to isolate molecules that selectively disrupt these interactions, and (3) elucidating the mechanisms of action of the most promising CPs at the molecular and cellular level. These experiments will provide first-in-class drug leads suitable for further development, and will also demonstrate a rapid, inexpensive approach to drug discovery for previously overlooked targets.
Public Health Relevance: Despite their fundamental roles in disease biology, transcription factors have been dismissed as "undruggable" due to their structural properties. This proposal outlines a general strategy for targeting these proteins for therapeutic intervention, and applies this strategy to diverse transcription factors that cause human cancer. Validation of these and other overlooked drug targets would be a true game-changer for drug development in every major disease field.
描述(由申请人提供)
摘要:Drugging the Undruggable:Myc、STAT 3和HSF 1等转录因子是新型癌症治疗的关键靶点。由于它们缺乏传统药物靶点的结构特征,这些蛋白质通常被归类为"不可用药的"。“这种假设是永久的事实,尽管密集的筛选工作使用传统的方法,有很少的已知化合物靶向转录因子。然而,有效的天然产物,如环孢霉素和雷帕霉素可以结合不同的,非传统的目标,否则会被忽视。环肽类似于这些天然产物大环化合物,因此具有靶向有希望的蛋白质的潜力,包括转录因子,这些蛋白质以前被认为是"不可药用的"。“需要新的筛选技术来发现生物活性环肽(CP)。我们最近描述了一种方法,遗传编码CP库的表型选择在酵母酿酒酵母。由于转录是如此基本的过程,因此在活生物体中进行选择以确保在完整真核转录机制的背景下对靶蛋白的活性和选择性是至关重要的。该技术允许在一天内在活细胞中筛选数千万个CP,而无需昂贵的机器人,并为二次测试和优化命中提供了快速途径。该提案描述了该方法在发现抑制与癌症有关的多种人类转录因子的CP中的应用。这将通过以下方式实现:(1)工程化酵母选择菌株,其报告Myc、STAT 3和HSF 1的蛋白质-蛋白质和蛋白质-DNA相互作用,(2)将CP文库应用于选择菌株以分离选择性地破坏这些相互作用的分子,以及(3)在分子和细胞水平上阐明最有希望的CP的作用机制。这些实验将提供一流的药物线索,适合进一步开发,也将展示一种快速,廉价的方法来发现药物,以前被忽视的目标。
公共卫生相关性:尽管转录因子在疾病生物学中起着重要作用,但由于其结构特性,它们被认为是"不可治疗的"。该提案概述了针对这些蛋白质进行治疗干预的一般策略,并将该策略应用于导致人类癌症的多种转录因子。这些和其他被忽视的药物靶点的验证将是每个主要疾病领域药物开发的真正游戏规则改变者。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Peptide bicycles that inhibit the Grb2 SH2 domain.
- DOI:10.1002/cbic.201200175
- 发表时间:2012-07-09
- 期刊:
- 影响因子:3.2
- 作者:Quartararo, Justin S.;Wu, Pianpian;Kritzer, Joshua A.
- 通讯作者:Kritzer, Joshua A.
Structured cyclic peptides that bind the EH domain of EHD1.
- DOI:10.1021/bi500744q
- 发表时间:2014-07-29
- 期刊:
- 影响因子:2.9
- 作者:Kamens, Alissa J.;Eisert, Robyn J.;Corlin, Tiffany;Baleja, James D.;Kritzer, Joshua A.
- 通讯作者:Kritzer, Joshua A.
A bicyclic peptide scaffold promotes phosphotyrosine mimicry and cellular uptake.
双环肽支架促进磷酸酪氨酸模拟和细胞摄取。
- DOI:10.1016/j.bmc.2014.09.050
- 发表时间:2014
- 期刊:
- 影响因子:3.5
- 作者:Quartararo,JustinS;Eshelman,MatthewR;Peraro,Leila;Yu,Hongtao;Baleja,JamesD;Lin,Yu-Shan;Kritzer,JoshuaA
- 通讯作者:Kritzer,JoshuaA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua A Kritzer其他文献
How to be quick on the uptake
如何快速理解
- DOI:
10.1038/nchembio.2183 - 发表时间:
2016-09-20 - 期刊:
- 影响因子:13.700
- 作者:
Joshua A Kritzer - 通讯作者:
Joshua A Kritzer
Magic bullets in nature's arsenal
大自然武库中的“魔弹”
- DOI:
10.1038/nchembio.407 - 发表时间:
2010-08-01 - 期刊:
- 影响因子:13.700
- 作者:
Joshua A Kritzer - 通讯作者:
Joshua A Kritzer
Joshua A Kritzer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua A Kritzer', 18)}}的其他基金
Developing Autophagy-Targeting Chimeras and Optimizing Cell Penetration of Large-Molecule Therapeutics
开发自噬靶向嵌合体并优化大分子治疗的细胞渗透
- 批准号:
10558145 - 财政年份:2023
- 资助金额:
$ 230.25万 - 项目类别:
High-Throughput Assays for Inhibitors of Understudied Bacterial Proteases
正在研究的细菌蛋白酶抑制剂的高通量测定
- 批准号:
9118235 - 财政年份:2015
- 资助金额:
$ 230.25万 - 项目类别:
High-Throughput Assays for Inhibitors of Understudied Bacterial Proteases
正在研究的细菌蛋白酶抑制剂的高通量测定
- 批准号:
8817739 - 财政年份:2015
- 资助金额:
$ 230.25万 - 项目类别:
High-Throughput Assays for Inhibitors of Understudied Bacterial Proteases
正在研究的细菌蛋白酶抑制剂的高通量测定
- 批准号:
9321116 - 财政年份:2015
- 资助金额:
$ 230.25万 - 项目类别:
Rapid Generation of Isoform-Selective Histone Deacetylase Inhibitors
快速生成异构体选择性组蛋白脱乙酰酶抑制剂
- 批准号:
8030563 - 财政年份:2011
- 资助金额:
$ 230.25万 - 项目类别:
Rapid Generation of Isoform-Selective Histone Deacetylase Inhibitors
快速生成异构体选择性组蛋白脱乙酰酶抑制剂
- 批准号:
8215725 - 财政年份:2011
- 资助金额:
$ 230.25万 - 项目类别:
Mechanism of Amyloid Inhibition by Small Molecules
小分子抑制淀粉样蛋白的机制
- 批准号:
7113342 - 财政年份:2006
- 资助金额:
$ 230.25万 - 项目类别:
Mechanism of Amyloid Inhibition by Small Molecules
小分子抑制淀粉样蛋白的机制
- 批准号:
7474647 - 财政年份:2006
- 资助金额:
$ 230.25万 - 项目类别:
Mechanism of Amyloid Inhibition by Small Molecules
小分子抑制淀粉样蛋白的机制
- 批准号:
7454964 - 财政年份:2006
- 资助金额:
$ 230.25万 - 项目类别:
相似海外基金
Identifying Patterns of BMI Development and Associated Behavioral, Social, Environmental, Genetic, and Biological Factors for Children from 3-10 Years
确定 3-10 岁儿童的 BMI 发展模式以及相关行为、社会、环境、遗传和生物因素
- 批准号:
10713863 - 财政年份:2023
- 资助金额:
$ 230.25万 - 项目类别:
Study of sex-specific biological factors underlying cognitive function and cardiovascular outcomes
认知功能和心血管结局背后的性别特异性生物学因素的研究
- 批准号:
461801 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Operating Grants
Understanding the link between sociocultural and biological factors to brain health across race & ethnicity in midlife
了解社会文化和生物因素与跨种族大脑健康之间的联系
- 批准号:
10429375 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Clinical and Biological Factors Predicting Lung Transplant Textbook Outcomes (U01)
预测肺移植教科书结果的临床和生物学因素(U01)
- 批准号:
10677558 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Understand biological factors underlying early childhood caries disparity from the oral microbiome in early infancy
从婴儿早期口腔微生物组了解儿童早期龋齿差异背后的生物因素
- 批准号:
10765136 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Clinical and Biological Factors Predicting Lung Transplant Textbook Outcomes (U01)
预测肺移植教科书结果的临床和生物学因素(U01)
- 批准号:
10431130 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Understand biological factors underlying early childhood caries disparity from the oral microbiome in early infancy
从婴儿早期口腔微生物组了解儿童早期龋齿差异背后的生物因素
- 批准号:
10666930 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Understand biological factors underlying early childhood caries disparity from the oral microbiome in early infancy
从婴儿早期口腔微生物组了解儿童早期龋齿差异背后的生物学因素
- 批准号:
10443354 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Understand biological factors underlying early childhood caries disparity from the oral microbiome in early infancy
从婴儿早期口腔微生物组了解儿童早期龋齿差异背后的生物学因素
- 批准号:
10612957 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:
Understanding the link between sociocultural and biological factors to brain health across race & ethnicity in midlife
了解社会文化和生物因素与跨种族大脑健康之间的联系
- 批准号:
10627936 - 财政年份:2022
- 资助金额:
$ 230.25万 - 项目类别:














{{item.name}}会员




